ALEMBIC PHARMA share price has zoomed 5% and is presently trading at Rs 1,133.7.
Meanwhile, the BSE HEALTHCARE index is at 38,340.0 (up 0.5%).
Among the top gainers in the BSE HEALTHCARE index today are DR. LAL PATHLABS (up 2.5%) and POLY MEDICURE (up 1.7%).
Jubilant Pharmova (down 2.9%) and ASTER DM HEALTHCARE (down 1.1%) are among the top losers today.
Over the last one year, ALEMBIC PHARMA has moved up from Rs 658.4 to Rs 1,133.7, registering a gain of Rs 475.3 (up 72.2%).
On the other hand, the BSE HEALTHCARE index has moved up from 26,342.4 to 38,340.0, registering a gain of 45.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 94.7%), Lupin (up 93.5%) and Cadila Healthcare (up 93.2%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,572.5 .
The top losers among the BSE Sensex today are Reliance Ind. (down 2.8%) and Kotak Bank (down 2.6%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 24,534.0 . NTPC and HDFC Bank are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,795.1 to 80,572.5, registering a gain of 13,777.3 points (up 20.6%).
ALEMBIC PHARMA net profit grew 10.9% YoY to Rs 1,786 million for the quarter ended March 2024, compared to a profit of Rs 1,611 million a year ago. Net sales rose 7.9% to Rs 15,170 million during the period as against Rs 14,065 million in January-March 2023.
For the year ended March 2024, ALEMBIC PHARMA reported 80.1% increase in net profit to Rs 6,158 million compared to net profit of Rs 3,420 million during FY23. Revenue of the company grew 10.2% to Rs 62,286 million during FY24.
The current Price to earnings ratio of ALEMBIC PHARMA, based on rolling 12 month earnings, stands at 36.1.
Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA Gains 5%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!